lipid modifying agents	are	drugs
lipid modifying agents	treat	hyperlipidemia
lipid modifying agents	reduce	LDL‑cholesterol
lipid modifying agents	increase	HDL‑cholesterol
lipid modifying agents	lower	triglycerides
lipid modifying agents	prevent	atherosclerosis
lipid modifying agents	lower	cardiovascular risk
lipid modifying agents	are	statins
lipid modifying agents	are	fibrates
lipid modifying agents	are	niacin
lipid modifying agents	are	bile‑acid sequestrants
lipid modifying agents	are	PCSK9 inhibitors
lipid modifying agents	are	omega‑3 fatty acids
statins	inhibit	HMG‑CoA reductase
statins	cause	myopathy
statins	cause	hepatotoxicity
statins	are	first‑line therapy
fibrates	activate	PPAR‑α
fibrates	reduce	VLDL
fibrates	cause	gallstones
niacin	increases	HDL‑cholesterol
niacin	causes	flushing
niacin	reduces	LDL‑cholesterol
bile‑acid sequestrants	bind	bile acids
bile‑acid sequestrants	increase	LDL‑receptor expression
PCSK9 inhibitors	inhibit	PCSK9
PCSK9 inhibitors	reduce	LDL‑cholesterol
PCSK9 inhibitors	are	monoclonal antibodies
omega‑3 fatty acids	reduce	triglycerides
omega‑3 fatty acids	may	reduce inflammation
lipid modifying agents	used	in statin‑resistant patients
lipid modifying agents	used	in statin‑intolerant patients
lipid modifying agents	used	in familial hypercholesterolemia
lipid modifying agents	used	in metabolic syndrome
lipid modifying agents	used	in diabetes
lipid modifying agents	used	in chronic kidney disease
lipid modifying agents	used	in liver disease
lipid modifying agents	used	in post‑bariatric surgery
lipid modifying agents	used	in HIV
lipid modifying agents	used	in cancer
lipid modifying agents	combined	with ezetimibe
lipid modifying agents	combined	with niacin
lipid modifying agents	combined	with fibrates
lipid modifying agents	combined	with omega‑3
lipid modifying agents	combined	with PCSK9 inhibitors
lipid modifying agents	combined	with bile‑acid sequestrants
lipid modifying agents	combined	with statins
lipid modifying agents	combined	with ezetimibe	reduces	LDL‑cholesterol
lipid modifying agents	combined	with niacin	increases	HDL‑cholesterol
lipid modifying agents	combined	with fibrates	lowers	triglycerides
lipid modifying agents	combined	with omega‑3	lowers	triglycerides
lipid modifying agents	combined	with PCSK9 inhibitors	lowers	LDL‑cholesterol
lipid modifying agents	combined	with bile‑acid sequestrants	lowers	LDL‑cholesterol
lipid modifying agents	combined	with statins	lowers	LDL‑cholesterol
lipid modifying agents	combined	with ezetimibe	reduces	statin side effects
lipid modifying agents	combined	with niacin	reduces	flushing
lipid modifying agents	combined	with fibrates	reduces	myopathy
lipid modifying agents	combined	with omega‑3	reduces	cardiovascular events
lipid modifying agents	combined	with PCSK9 inhibitors	reduces	cardiovascular events
lipid modifying agents	combined	with bile‑acid sequestrants	reduces	cardiovascular events
lipid modifying agents	combined	with statins	reduces	cardiovascular events
lipid modifying agents	combined	with ezetimibe	improves	LDL‑target attainment
lipid modifying agents	combined	with niacin	improves	HDL‑target attainment
lipid modifying agents	combined	with fibrates	improves	triglyceride target attainment
lipid modifying agents	combined	with omega‑3	improves	triglyceride target attainment
lipid modifying agents	combined	with PCSK9 inhibitors	improves	LDL‑target attainment
lipid modifying agents	combined	with bile‑acid sequestrants	improves	LDL‑target attainment
lipid modifying agents	combined	with statins	improves	LDL‑target attainment
lipid modifying agents	combined	with ezetimibe	reduces	liver enzyme elevation
lipid modifying agents	combined	with niacin	reduces	liver enzyme elevation
lipid modifying agents	combined	with fibrates	reduces	liver enzyme elevation
lipid modifying agents	combined	with omega‑3	reduces	liver enzyme elevation
lipid modifying agents	combined	with PCSK9 inhibitors	reduces	liver enzyme elevation
lipid modifying agents	combined	with bile‑acid sequestrants	reduces	liver enzyme elevation
lipid modifying agents	combined	with statins	reduces	liver enzyme elevation
lipid modifying agents	combined	with ezetimibe	reduces	myopathy
lipid modifying agents	combined	with niacin	reduces	myopathy
lipid modifying agents	combined	with fibrates	reduces	myopathy
lipid modifying agents	combined	with omega‑3	reduces	myopathy
lipid modifying agents	combined	with PCSK9 inhibitors	reduces	myopathy
lipid modifying agents	combined	with bile‑acid sequestrants	reduces	myopathy
lipid modifying agents	combined	with statins	reduces	myopathy
lipid modifying agents	combined	with ezetimibe	reduces	gastrointestinal side effects
lipid modifying agents	combined	with niacin	reduces	gastrointestinal side effects
lipid modifying agents	combined	with fibrates	reduces	gastrointestinal side effects
lipid modifying agents	combined	with omega‑3	reduces	gastrointestinal side effects
lipid modifying agents	combined	with PCSK9 inhibitors	reduces	gastrointestinal side effects
lipid modifying agents	combined	with bile‑acid sequestrants	reduces	gastrointestinal side effects
lipid modifying agents	combined	with statins	reduces	gastrointestinal side effects
lipid modifying agents	combined	with ezetimibe	improves	patient adherence
lipid modifying agents	combined	with niacin	improves	patient adherence
lipid modifying agents	combined	with fibrates	improves	patient adherence
lipid modifying agents	combined	with omega‑3	improves	patient adherence
lipid modifying agents	combined	with PCSK9 inhibitors	improves	patient adherence
lipid modifying agents	combined	with bile‑acid sequestrants	improves	patient adherence
lipid modifying agents	combined	with statins	improves	patient adherence
lipid modifying agents	combined	with ezetimibe	reduces	cost
lipid modifying agents	combined	with niacin	reduces	cost
lipid modifying agents	combined	with fibrates	reduces	cost
lipid modifying agents	combined	with omega‑3	reduces	cost
